Company faces class action lawsuit for alleged material misstatements regarding FDA approval prospects and manufacturing capabilities. Stock experienced significant declines (3.1% in August 2024 and 24.45% in December 2025) following disclosure of manufacturing issues and FDA rejection of accelerated approval. Lead product development timeline was delayed by approximately one year.
Allegations of deficient manufacturing, missed FDA submission timelines, and overstated regulatory prospects for key product INO-3107 suggest significant product development and commercialization challenges.
The company faces a class action lawsuit alleging material misstatements about manufacturing capabilities and regulatory prospects. The FDA rejected accelerated approval for INO-3107, resulting in a 24.45% stock price decline. The lawsuit claims investors suffered damages due to false and misleading public statements.
Company faces allegations of making false and misleading statements regarding manufacturing deficiencies in its CELLECTRA device, failure to disclose inability to submit BLA by promised timeline, and overstated regulatory and commercial prospects for INO-3107 product, resulting in investor damages.
The company is facing a securities fraud class action lawsuit alleging material misstatements about manufacturing capabilities and regulatory timelines for its lead drug candidate. Significant stock price declines (3.1% and 24.45%) followed disclosure of manufacturing issues and FDA rejection of accelerated review status, indicating loss of investor confidence and potential financial liability.
The company is the subject of a securities class action lawsuit alleging material misstatements and omissions regarding manufacturing deficiencies, regulatory prospects, and FDA approval timelines for its INO-3107 product. Investors suffered damages when the true details entered the market, indicating significant corporate governance and disclosure failures.
The company is the subject of a securities class action lawsuit alleging material misstatements about manufacturing deficiencies, regulatory prospects, and FDA approval timelines for its key drug candidate INO-3107. Investors who purchased securities during the class period (October 10, 2023 - December 26, 2025) allegedly suffered damages.
The company is accused of making materially false and misleading statements about manufacturing deficiencies, regulatory timelines, and commercial prospects. These allegations of securities fraud and investor harm directly damage the company's credibility and reputation.
The company is the subject of a securities class action lawsuit alleging material misstatements and omissions regarding manufacturing deficiencies, regulatory prospects, and FDA submission timelines for a key drug candidate. Investors who purchased during the class period are seeking compensation for damages.
The company is the subject of a securities fraud class action alleging false or misleading statements about device manufacturing and FDA regulatory pathways that artificially inflated stock prices during the class period.
The company is the subject of a securities class action lawsuit alleging material misstatements and omissions regarding manufacturing deficiencies, regulatory prospects, and FDA submission timelines. These allegations suggest investor losses and regulatory/commercial setbacks for the company's key product INO-3107.
The company faces a securities class action lawsuit alleging material misstatements about manufacturing capabilities and regulatory prospects. The FDA rejected accelerated approval for its lead candidate INO-3107, accepting only standard review, resulting in a significant 24.45% stock price decline. The company has indicated it will not pursue standard approval and must seek FDA guidance on alternative pathways.
Allegations of deficient manufacturing, missed FDA submission timelines, insufficient justification for accelerated approval, and overstated regulatory and commercial prospects.
The company is accused of making false and misleading statements to the market regarding manufacturing deficiencies, unrealistic FDA filing timelines, and insufficient evidence for regulatory approval. These allegations resulted in investor losses and triggered a securities fraud class action lawsuit.
The company is the subject of a securities class action lawsuit alleging material misstatements and omissions regarding manufacturing deficiencies, regulatory prospects, and BLA submission timelines. Investors claim to have suffered damages as a result of these false and misleading statements.
Company faces class action lawsuit for allegedly making false statements about manufacturing capabilities and regulatory prospects. FDA rejected accelerated approval pathway for INO-3107, resulting in 24.45% stock price decline on December 29, 2025.
The company faces a securities class action lawsuit alleging material misstatements and omissions regarding FDA approval timelines and manufacturing issues. Management allegedly provided repeated assurances about accelerated approval and submission timelines that proved inaccurate, resulting in investor losses.
The company is accused of making false and misleading statements about manufacturing capabilities for its CELLECTRA device and overstating regulatory prospects for INO-3107. Allegations include deficient manufacturing and insufficient information for FDA accelerated approval, resulting in investor damages.
The company is the subject of a securities class action lawsuit alleging material misrepresentations regarding FDA regulatory pathway eligibility. Management allegedly made false claims about accelerated approval prospects that formed a core part of the investment thesis, and the FDA's rejection of accelerated approval eligibility resulted in negative market reaction.
The company is the subject of a securities class action lawsuit alleging material misstatements and omissions regarding manufacturing deficiencies, regulatory prospects, and FDA submission timelines. Investors suffered damages when the true details became public.
The company faces a class action lawsuit alleging false and misleading statements about manufacturing capabilities and regulatory prospects. The FDA rejected accelerated approval for INO-3107, accepting it only under standard review, resulting in a 24.45% stock price decline on December 29, 2025. These developments indicate significant regulatory setbacks and legal liability.
The company is accused of misleading investors about manufacturing capabilities and regulatory prospects for its key product. Stock declined significantly (3.1% on August 9, 2024 and 24.45% on December 29, 2025) following disclosure of delays and failure to qualify for accelerated FDA review, indicating loss of investor confidence and potential financial liability from the class action.
Articles that tag INO but are mainly about other companies.
INO-3112, an HPV-directed therapeutic vaccine candidate, is highlighted as a notable program among emerging therapies expected to reshape the HNSCC immunotherapy market.
Zacks Rank #2 (Buy) with exceptional 69.05% average four-quarter earnings surprise, indicating strong earnings momentum and investor confidence in the company's vaccine development pipeline.
Zacks Rank #2 (Buy) with rising P/E and exceptional 69.05% average four-quarter earnings surprise, demonstrating strong earnings growth acceleration.
Developing INO-3112, an investigational immunotherapy in clinical trials for HNSCC, with potential to capture market share in the expanding treatment landscape.
Developing INO-3112, an investigational therapy in the expanding HNSCC pipeline. The company is positioned to benefit from the growing market and emerging treatment paradigms.
INO-5401 immunotherapy program is described as promising but clinically challenging in GBM; also announced collaboration with Akeso for combination therapy, showing progress but with acknowledged development challenges.
Company is subject to a filed securities class action lawsuit, though specific allegations are not detailed in the provided excerpt.
Company is subject to securities class action lawsuit with April 7 deadline, indicating alleged investor losses exceeding $100K.
Company is defendant in securities class action lawsuit with investors having losses in excess of $100,000, indicating material financial harm to shareholders.
Company is subject to securities class action lawsuit targeting investors with significant losses, indicating material misstatements or disclosure failures.
Company is subject to class action lawsuit filed by Pomerantz LLP for alleged securities fraud and unlawful business practices by officers and/or directors.
Company is subject to a securities class action lawsuit filed by Rosen Law Firm, indicating alleged securities fraud or material misstatements to investors.
Company is subject to a securities class action lawsuit filed by Rosen Law Firm, though specific allegations are not detailed in the provided excerpt.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
